Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Three ACTs for Uncomplicated Malaria in DRC Children
NCT02940756Phase 4Completed
- Sponsor
- Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Plasmodium falciparum malaria comparing Artesunate-Amodiaquine, Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine (3 arms). Primary endpoint: PCR-adjusted efficacy at 42 days. Started Mar 2017; status: completed.
02
Drugs
artesunate + amodiaquineartemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT02940756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940756.